As of Jan. 1, 2019, a prescriber must offer to a patient a prescription for naloxone hydrochloride or other FDA-approved drug for the complete or partial reversal of opioid depression when one or more of the following conditions are present:

1. The prescription dosage for the patient is 90 or more morphine milligram equivalents of an opioid medication per day. (See this CDC document on how to calculate MME.)
2. An opioid medication is prescribed concurrently with a prescription for benzodiazepine.
3. The patient presents with an increased risk for overdose, including a patient with a history of overdose, a patient with a history of substance use disorder or a patient at risk for returning to a high dose of opioid medication to which the patient is no longer tolerant.

Additionally, a prescriber must provide education to a patient, or the patient’s guardian if patient is a minor, receiving a prescription per the above circumstance on overdose prevention and the use of naloxone hydrochloride or other FDA-approved drug for the complete or partial reversal of opioid depression. AB 2760